Meet the newest ethical and legal challenge of obtaining and using data via the internet: The dark web

Wednesday, March 1, 2017

Are you afraid of the dark? What thoughts come to mind when you hear the word “dark”? Scary? Hidden? Sinister? Mysterious? Shadowy? The opposite of dark, of course, is “light” — and this signifies transparency, full disclosure, openness, and clarity. It is in this context that research professionals increasingly are using what is called the “dark web” to collect and use data for studies that are looking at activities that are often, but not always, illegal. What makes the dark web both intriguing and worrisome for researchers is not the kind of information it includes but rather the methods used to obtain the data (neither the usual search engines nor by hacking passwords).

[Read More]

Foundation Medicine appoints Troy Cox CEO

Monday, January 9, 2017

Foundation Medicine has announced that, as part of the succession of its executive leadership, the board of directors has appointed Troy Cox, a highly regarded global biopharma leader, as chief executive officer to succeed Michael Pellini, M.D. Dr. Pellini, who has served as chief executive officer of the company since 2011, has been appointed chairman of the company’s board of directors. Alexis Borisy, founding chief executive officer and current chairman of the board for Foundation Medicine, will continue to serve on the board of directors. Cox will also join the board of directors. All of these changes will become effective by February 6, 2017.

[Read More]

FEI partners to form Cryo-EM research consortium

Tuesday, April 5, 2016

FEI has partnered to form the “Cambridge Pharmaceutical Cryo-EM Consortium.” Partners include five pharmaceutical companies—Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Center. As part of the three-year agreement, FEI will provide sample preparation and data collection services on a Titan Krios cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.

[Read More]

Wearables track drug effectiveness in Parkinson’s patients

Monday, January 18, 2016

Cynapsus and the Michael J. Fox Foundation (MJFF) are partnering to incorporate a wearable device into a phase III study of patients with Parkinson’s disease. Similar to a smartwatch, the device is equipped with motion sensors to detect when patients have an “OFF” episode—a period where medicine stops working and motor impairment symptoms return. The symptoms include muscle stiffness or problems with starting movements, such as starting to walk or getting out of a chair.

[Read More]

Evotec, UCB ink management agreement

Thursday, January 7, 2016

Evotec has announced an EVT Execute collaboration aimed at providing a complete solution to UCB‘s global sample management requirements. Evotec will manage UCB’s compound collection out of its state-of-the-art sample management facility in Toulouse, France. The agreement covers an initial period of five years.

[Read More]

Zogenix expands senior leadership team

Friday, July 10, 2015

Zogenix, a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, has appointed Gail M. Farfel, Ph.D., executive vice president and chief development officer, and Thierry Darcis, M.D., M.B.A., executive vice president and general manager, Europe.

[Read More]